Sanofi

Investors

We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.

Nadège Bailleul, Mirage Operator, Val de Reuil, France

Second Quarter 2025

Second quarter 2025 results were reviewed by management during a live audio webcast with the financial community on July 31, 2025. The presentation was followed by a Q&A session.

Press Releases


September 4, 2025
Media Update: ERS: new data across Sanofi’s immunology pipeline reinforce leadership in respiratory diseases

September 4, 2025
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

September 3, 2025
Media Update: EADV: Sanofi builds on legacy in immunology with new data highlighting advances in treatment of chronic inflammatory skin diseases

Upcoming Events

3Sep

2025

J.P. Morgan European Healthcare CEO Call Series

15:00 CET (Virtual)

Conferences

Discover more

4Sep

2025

Wells Fargo Healthcare Conference

08:00 - 17:00 EDT (Boston)

Conferences


9Sep

2025

Kepler Cheuvreux Autumn Conference

08:00 - 16:00 CET (Paris)

Conferences

Discover more

Karine Roblot, wearing a light green protective suit, operating steel equipment with lots of valves, gauges and tubing
Karine Roblot, Vaccine Formulation Technician, Val de Reuil, France

2024 20-F

Presenting our 2024 FORM 20-F.

30th Consecutive Year of Dividend Increase

Dr. Lingaraju checks the health of Manikantan as his sister Geetha watches closely inside the Billigiri Ranganathaswamy Temple Tiger Reserve in Chamrajanagara district, Karnataka state, India

Environment, Social, Governance

As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.

Contact Our Investor Relations Team

For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00